Zhongyuan Xiehe stem cell new drug has not been approved clinically

Zhongyuan Xiehe announced last night that the application for registration of heavy-duty stem cell drug umbilical cord mesenchymal stem cell anti fibrosis injection was not approved Last week, it was reported that the drug's review status had gone back from "under review" to "under review", questioning whether it could be approved for clinical use in the short term It is understood that the umbilical cord mesenchymal stem cell anti liver fibrosis injection was jointly declared by Tianjin Heze Stem Cell Technology Co., Ltd and zebio Technology Co., Ltd under the company After the declaration status changed to "in approval" at the beginning of the month, the stock price of the company continued to rise The market expects that this is the first approved clinical stem cell drug after the new deal of stem cell is released At present, there is no specific drug for the treatment of liver fibrosis According to the announcement, the reason for not being approved is not in conformity with the provisions of the measures for the administration of drug registration The company also announced that the registration application of two drugs declared by cnpec in the same period was not approved Recently, the Ministry of science and technology of the people's Republic of China issued the implementation plan for key projects of stem cell and translational medicine of national key research and development plan (Draft for comments), launched the pilot work for key projects of "stem cell and translational medicine" of national key research and development plan, strengthened the investment and layout in stem cell foundation and transformation, and ignited the enthusiasm of the market for stem cell sector.